Aviv Biomedical has been awarded a two year NIH Phase IIb SBIR grant (5R44TR001635-04 & 5R44TR001635-05) to make additional improvements, and prepare the Bilirubin Hematofluorometer for regulatory approval. Aviv has already completed Phase I (proof-of-principle), and Phase II (successful commercialization) funding. NIH SBIR Phase IIb funding is awarded to proven devices that require additional effort to become approved medical devices. With this grant NIH’s investment in this project approaches the $3 million dollar mark.
Earlier Phase II funding resulted in publication of recommendations for the use of the bilirubin binding capacity measurements obtained by the hematofluorometer1. Devices are now in clinical studies at multiple hospital sites.
- Lamola, A. A.; Bhutani, V. K.; Du, L.; Castillo Cuadrado, M.; Chen, L.; Shen, Z.; Wong, R. J.; Stevenson, D. K., “Neonatal bilirubin binding capacity discerns risk of neurological dysfunction.” Pediatr Res 2015, 77 (2), 334-339.
Research reported in this press release was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number R44TR001635. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.